152 related articles for article (PubMed ID: 21816036)
1. Innegligible musculoskeletal disorders caused by zoledronic acid in adjuvant breast cancer treatment: a meta-analysis.
Zhou WB; Zhang PL; Liu XA; Yang T; He W
J Exp Clin Cancer Res; 2011 Aug; 30(1):72. PubMed ID: 21816036
[TBL] [Abstract][Full Text] [Related]
2. 5-year follow-up of a randomized controlled trial of immediate versus delayed zoledronic acid for the prevention of bone loss in postmenopausal women with breast cancer starting letrozole after tamoxifen: N03CC (Alliance) trial.
Wagner-Johnston ND; Sloan JA; Liu H; Kearns AE; Hines SL; Puttabasavaiah S; Dakhil SR; Lafky JM; Perez EA; Loprinzi CL
Cancer; 2015 Aug; 121(15):2537-43. PubMed ID: 25930719
[TBL] [Abstract][Full Text] [Related]
3. Adjuvant therapy with zoledronic acid in patients with breast cancer: a systematic review and meta-analysis.
Valachis A; Polyzos NP; Coleman RE; Gnant M; Eidtmann H; Brufsky AM; Aft R; Tevaarwerk AJ; Swenson K; Lind P; Mauri D
Oncologist; 2013; 18(4):353-61. PubMed ID: 23404816
[TBL] [Abstract][Full Text] [Related]
4. Immediate Administration of Zoledronic Acid Reduces Aromatase Inhibitor-Associated Bone Loss in Postmenopausal Women With Early Breast Cancer: 12-month analysis of the E-ZO-FAST trial.
Llombart A; Frassoldati A; Paija O; Sleeboom HP; Jerusalem G; Mebis J; Deleu I; Miller J; Schenk N; Neven P
Clin Breast Cancer; 2012 Feb; 12(1):40-8. PubMed ID: 22014381
[TBL] [Abstract][Full Text] [Related]
5. Economic evaluation of zoledronic acid for the prevention of osteoporotic fractures in postmenopausal women with early-stage breast cancer receiving aromatase inhibitors in the UK.
Logman JFS; Heeg BMS; Botteman MF; Kaura S; van Hout BA
Ann Oncol; 2010 Jul; 21(7):1529-1536. PubMed ID: 19955334
[TBL] [Abstract][Full Text] [Related]
6. Association between timing of zoledronic acid infusion and hip fracture healing.
Colón-Emeric C; Nordsletten L; Olson S; Major N; Boonen S; Haentjens P; Mesenbrink P; Magaziner J; Adachi J; Lyles KW; Hyldstrup L; Bucci-Rechtweg C; Recknor C;
Osteoporos Int; 2011 Aug; 22(8):2329-36. PubMed ID: 21153021
[TBL] [Abstract][Full Text] [Related]
7. Immediate versus delayed zoledronic acid for prevention of bone loss in postmenopausal women with breast cancer starting letrozole after tamoxifen-N03CC.
Hines SL; Mincey B; Dentchev T; Sloan JA; Perez EA; Johnson DB; Schaefer PL; Alberts S; Liu H; Kahanic S; Mazurczak MA; Nikcevich DA; Loprinzi CL
Breast Cancer Res Treat; 2009 Oct; 117(3):603-9. PubMed ID: 19214743
[TBL] [Abstract][Full Text] [Related]
8. Influence of zoledronic acid on disseminated tumor cells in primary breast cancer patients.
Solomayer EF; Gebauer G; Hirnle P; Janni W; Lück HJ; Becker S; Huober J; Krämer B; Wackwitz B; Wallwiener D; Fehm T
Ann Oncol; 2012 Sep; 23(9):2271-2277. PubMed ID: 22383680
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of a once-yearly intravenous zoledronic acid 5 mg for fracture prevention in elderly postmenopausal women with osteoporosis aged 75 and older.
Boonen S; Black DM; Colón-Emeric CS; Eastell R; Magaziner JS; Eriksen EF; Mesenbrink P; Haentjens P; Lyles KW
J Am Geriatr Soc; 2010 Feb; 58(2):292-9. PubMed ID: 20070415
[TBL] [Abstract][Full Text] [Related]
10. Strontium-89 plus zoledronic acid versus zoledronic acid for patients with painful bone metastatic breast cancer.
Yamada K; Kaise H; Taguchi T; Horiguchi J; Takao S; Suzuki M; Kubota T; Miura D; Narui K; Tawaraya K; Machida Y; Akazawa K; Kohno N; Ishikawa T;
J Bone Miner Metab; 2022 Nov; 40(6):998-1006. PubMed ID: 36042056
[TBL] [Abstract][Full Text] [Related]
11. Managing bone health with zoledronic acid: a review of randomized clinical study results.
Hadji P
Climacteric; 2011 Jun; 14(3):321-32. PubMed ID: 21182431
[TBL] [Abstract][Full Text] [Related]
12. The incidence of osteonecrosis of the jaw in patients receiving 5 milligrams of zoledronic acid: data from the health outcomes and reduced incidence with zoledronic acid once yearly clinical trials program.
Grbic JT; Black DM; Lyles KW; Reid DM; Orwoll E; McClung M; Bucci-Rechtweg C; Su G
J Am Dent Assoc; 2010 Nov; 141(11):1365-70. PubMed ID: 21037195
[TBL] [Abstract][Full Text] [Related]
13. Comparison of skeletal complications and treatment patterns associated with early vs. delayed zoledronic acid therapy in multiple myeloma.
Wu EQ; Bensimon AG; Marynchenko M; Namjoshi M; Guo A; Yu AP; Ericson SG; Raje N
Clin Lymphoma Myeloma Leuk; 2011 Aug; 11(4):326-35. PubMed ID: 21700528
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36-month results of the ZO-FAST Study.
Eidtmann H; de Boer R; Bundred N; Llombart-Cussac A; Davidson N; Neven P; von Minckwitz G; Miller J; Schenk N; Coleman R
Ann Oncol; 2010 Nov; 21(11):2188-2194. PubMed ID: 20444845
[TBL] [Abstract][Full Text] [Related]
15. Survival outcomes of neoadjuvant chemotherapy with zoledronic acid for HER2-negative breast cancer.
Ishikawa T; Akazawa K; Hasegawa Y; Tanino H; Horiguchi J; Miura D; Hayashi M; Kohno N
J Surg Res; 2017 Dec; 220():46-51. PubMed ID: 29180210
[TBL] [Abstract][Full Text] [Related]
16. Effect of (Neo)adjuvant zoledronic acid on disease-free and overall survival in clinical stage II/III breast cancer.
Aft RL; Naughton M; Trinkaus K; Weilbaecher K
Br J Cancer; 2012 Jun; 107(1):7-11. PubMed ID: 22617128
[TBL] [Abstract][Full Text] [Related]
17. Integrated analysis of zoledronic acid for prevention of aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole.
Brufsky A; Bundred N; Coleman R; Lambert-Falls R; Mena R; Hadji P; Jin L; Schenk N; Ericson S; Perez EA;
Oncologist; 2008 May; 13(5):503-14. PubMed ID: 18515735
[TBL] [Abstract][Full Text] [Related]
18. The new bisphosphonate, Zometa (zoledronic acid), decreases skeletal complications in both osteolytic and osteoblastic lesions: a comparison to pamidronate.
Lipton A; Small E; Saad F; Gleason D; Gordon D; Smith M; Rosen L; Kowalski MO; Reitsma D; Seaman J
Cancer Invest; 2002; 20 Suppl 2():45-54. PubMed ID: 12442349
[TBL] [Abstract][Full Text] [Related]
19. The efficacy of zoledronic acid in breast cancer adjuvant therapy: a meta-analysis of randomised controlled trials.
Yan T; Yin W; Zhou Q; Zhou L; Jiang Y; Du Y; Shao Z; Lu J
Eur J Cancer; 2012 Jan; 48(2):187-95. PubMed ID: 22100904
[TBL] [Abstract][Full Text] [Related]
20. Bisphosphonates and other bone agents for breast cancer.
Wong MH; Stockler MR; Pavlakis N
Cochrane Database Syst Rev; 2012 Feb; (2):CD003474. PubMed ID: 22336790
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
